Quality of life with second- or third-line nab-paclitaxel–based regimens in advanced non-small cell lung cancer
Journal article
Ponce Aix S. et al, (2020), Future Oncology
Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project.
Journal article
Mansoor W. et al, (2020), Int J Endocrinol, 2020
Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
Journal article
Genus T. et al, (2019), British Journal of Cancer
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Journal article
Morgensztern D. et al, (2018), Cancer, 124, 4667 - 4675
Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Conference paper
Morgensztern D. et al, (2018), JOURNAL OF THORACIC ONCOLOGY, 13, S489 - S489
Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma
Conference paper
Fennell D. et al, (2018), JOURNAL OF THORACIC ONCOLOGY, 13, S397 - S397
Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+
Conference paper
Talbot D. et al, (2018), JOURNAL OF THORACIC ONCOLOGY, 13, S498 - S499
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Journal article
Basu B. et al, (2018), Ann Oncol, 29, 1918 - 1925
Primary Ovarian Carcinoid: Extensive Clinical Experience With an Underrecognized Uncommon Entity.
Journal article
Preda VA. et al, (2018), Int J Gynecol Cancer, 28, 466 - 471
INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
Journal article
Tadman M. et al, (2018), Endocr Pract, 24, 189 - 194
1-Year Survival Rates for Neuroendocrine Tumor Patients in England
Conference paper
Genus T. et al, (2018), NEUROENDOCRINOLOGY, 106, 83 - 83
Incidence and Prevalence of Neuroendocrine Tumors in England
Conference paper
Genus T. et al, (2018), NEUROENDOCRINOLOGY, 106, 84 - 84
Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Conference paper
Genus T. et al, (2018), NEUROENDOCRINOLOGY, 106, 85 - 85
The incidence, diagnostic pathway and management of pulmonary carcinoid tumours in the UK: results from the National Lung NET pathway ('LEAP') Project
Conference paper
Ferguson S. et al, (2018), LUNG CANCER, 115, S17 - S18
Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+
Conference paper
Govindan R. et al, (2017), JOURNAL OF THORACIC ONCOLOGY, 12, S1839 - S1840
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Journal article
Talbot T. et al, (2017), Lung Cancer, 113, 115 - 120
ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
Conference paper
Morgensztern D. et al, (2017), ANNALS OF ONCOLOGY, 28
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
Journal article
Taylor C. et al, (2017), J Clin Oncol, 35, 1641 - 1649